EssilorLuxottica: Smart Glasses And Myopia Management Reinforce Long-Term Growth Story

EssilorLuxottica posted a third consecutive quarter of double-digit top-line sales growth and beat consensus, with smart glasses and Ray-Ban Meta prescription lens penetration rising above 30% as key upside drivers. The company is also expanding its addressable market through myopia management, the Stellest US rollout, and the Top Charoen acquisition. Management commentary implies double-digit sales CAGR and mid-teens EPS growth through 2028.

Analysis

The cleanest read-through is that EssilorLuxottica is not just winning on product; it is converting a higher-value mix into a broader ecosystem lock-in. Smart eyewear creates a durable attach-rate flywheel: once consumers buy into the frame, incremental lens upgrades, prescription fulfillment, and recurring replacement cycles become harder for competitors to dislodge. That shifts the profit pool away from commodity optics toward a higher-ARPU platform with better pricing power and lower churn.

Competitive pressure is likely to show up first in adjacent channels rather than direct head-to-head share loss. Independent optical retailers, private-label lens chains, and smaller premium eyewear brands may face margin compression as the category leader uses brand, distribution, and bundled services to raise switching costs. The expansion into myopia management also widens the moat by linking consumer optics with a quasi-healthcare value proposition, which could make reimbursement, doctor referral networks, and pediatric channel access more important than traditional retail shelf share.

The main risk is that consensus may be extrapolating the hardware adoption curve too aggressively. The near-term catalyst is still mix and penetration, but over 6-18 months the market will care about whether wearable glasses sustain repeat purchases after the novelty phase and whether prescription attachment stays above the current threshold once competition intensifies. A second-order risk is channel conflict: aggressive expansion through acquisitions and new products can pressure smaller partners and create execution drag if integration or inventory management slips.

From a contrarian standpoint, the setup may be better than the headline multiple suggests because investors often underwrite smart glasses as a consumer gadget rather than an operating-system-like distribution wedge. If prescription penetration continues rising, the earnings power is less cyclical than it appears, since every unit sold reinforces the installed base and enlarges the downstream lens opportunity. The asymmetric risk is not a demand collapse; it is a slower normalization of growth once the market fully prices the platform effect.

Key Decisions for Investors

• Long EO:FP / hold through the next 6-12 months if prescription attach remains above 30%; risk/reward favors upside as mix expansion should sustain mid-teens EPS growth even if unit growth normalizes.
• Pair trade: long EO:FP vs short a basket of regional optical retailers and low-moat eyewear names over 3-6 months; thesis is margin and share pressure from category leader ecosystem capture.
• Buy call spreads on EO:FP-equivalent exposure for 6-12 months if available in your local market; use defined risk to express the view that the market is underpricing the durability of the smart-glasses flywheel.
• Monitor pediatric/myopia reimbursement and US rollout milestones over the next 1-2 quarters; if adoption lags, trim exposure because the healthcare optionality is the least certain leg of the bull case.